Benjamin Trzaskoma
YOU?
Author Swipe
View article: Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies Open
Many people with hemophilia A (PwHA) undergo surgery in their lifetime, often because of complications of their disease. Emicizumab is the first bispecific monoclonal antibody prophylactic therapy for PwHA, and its efficacy and safety have…
View article: Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma
Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma Open
Omalizumab was associated with lung function improvements and circulating eosinophil counts reductions in adolescents with moderate-to-severe uncontrolled asthma. Findings emphasize the effect of omalizumab in young patients and the need t…
View article: Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis Open
ClinicalTrials.gov; Nos. NCT01366209, NCT00287716, and NCT00287729; URL: www.clinicaltrials.gov.
View article: Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO
Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO Open
ClinicalTrials.gov Identifier: NCT01922037.
View article: Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study Open
To the Editor: We describe results from a phase IV study in patients with chronic idiopathic urticaria (CIU) that provide an expanded view of the benefits of omalizumab treatment in protocol-defined responders and nonresponders and offer i…
View article: Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma Open
Background Recent efficacy studies of asthma biologics have included highly enriched patient populations. Using a similar approach, we examined factors that predict response to omalizumab to facilitate selection of patients most likely to …
View article: Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life
Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Open
A higher number of asthma triggers at baseline was associated with greater asthma severity and number of asthma exacerbations and lower QOL in children with severe/difficult-to-treat asthma.
View article: Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria
Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria Open
Basophils are believed to play an important role in the pathophysiology of chronic idiopathic/spontaneous urticaria (CIU/CSU) (Vonakis and Saini, 2008Vonakis B.M. Saini S.S. New concepts in chronic urticaria.Curr Opin Immunol. 2008; 20: 70…
View article: A randomized multicenter study evaluating Xolair persistence of response after long-term therapy
A randomized multicenter study evaluating Xolair persistence of response after long-term therapy Open
Continuation of omalizumab after long-term treatment results in continued benefit, as evidenced by improved symptom control and reduced exacerbation risk.
View article: Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies Open
Improvement in sleep was reported after the first dose of omalizumab. Sleep continued to improve throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatme…